Last reviewed · How we verify

NCT05535660

Lipid Profile as Predictor of Adverse Maternal and Neonatal Outcomes: A Pilot Study

Completed Last updated 7 November 2024
What this trial tests

trial testing Lipid panel in Hyperlipidemia in 111 participants. Completed in 5 August 2024.

Timeline
29 July 2022
Primary endpoint
5 August 2024
5 August 2024

Quick facts

Lead sponsorIcahn School of Medicine at Mount Sinai
StatusCompleted
Study typeOBSERVATIONAL
Enrollment111
Start date29 July 2022
Primary completion5 August 2024
Estimated completion5 August 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Icahn School of Medicine at Mount Sinai

Who can join

Adults 18 to 45, female only, with Hyperlipidemia or Pregnancy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to ascertain lipid profiles during pregnancy, specifically during the 24-28 week gestation and again near term at 36 weeks gestation. The research team are investigating whether lipid profiles can predict adverse maternal and neonatal outcomes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Hyperlipidemia

Currently open trials in the same condition.

Other Icahn School of Medicine at Mount Sinai trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05535660.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing